{"id":914482,"date":"2025-12-01T07:11:51","date_gmt":"2025-12-01T12:11:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/"},"modified":"2025-12-01T07:11:51","modified_gmt":"2025-12-01T12:11:51","slug":"autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/","title":{"rendered":"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON and GAITHERSBURG, Md., Dec.  01, 2025  (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company\u2019s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus\u2019 Board.<\/p>\n<p align=\"justify\">\u201cAutolus has entered a new phase of growth as a commercial-stage company. Ryan\u2019s deep experience guiding corporate strategy and development will be invaluable to our organization as we continue the momentum of our first commercial launch, and maximize the significant opportunity we have to expand obe-cel\u2019s reach in new indications in a focused and efficient manner,\u201d said Dr. Christian Itin, Autolus CEO.<\/p>\n<p align=\"justify\">\u201cAutolus is well-positioned with a foundation of strong clinical data supporting growth in current and future indications, supported by proven CAR T manufacturing expertise and established commercial capabilities. I look forward to contributing to the direction of the Company to expand obe-cel\u2019s opportunity to reach increasing numbers of patients in need,\u201d said Mr. Richardson.<\/p>\n<p align=\"justify\">Mr. Richardson previously served as Chief Strategy Officer and member of the Management Board of BioNTech during his tenure from September 2018 to September 2025. In addition to leading BioNTech\u2019s Corporate Development and Strategy, Capital Markets, and Investor Relations functions, Mr. Richardson played a central role in BioNTech\u2019s global expansion and transition to a commercial stage company, including its Initial Public Offering, subsequent private placement and follow-on equity financings, and multiple strategic business development and M&amp;A transactions. He served as Chairman of the Board of Directors of Instadeep Ltd., a leading global technology company active in the field of artificial intelligence and machine learning, following BioNTech\u2019s acquisition in 2023. Prior to BioNTech, Mr. Richardson was an Executive Director in J.P. Morgan\u2019s Global Healthcare Investment Banking team in London, where he worked on a wide range of strategic transactions from 2011 to 2018. Earlier in his career, Mr. Richardson served as a life sciences management consultant and health economist. He was the recipient of the 2004 Robert. R. Bosch Fellowship and a recipient of the 2018 Eisenhower Zhi-Xing Fellow in China.<\/p>\n<p align=\"justify\">Mr. Richardson holds an International MBA from the University of Chicago Booth School of Business, an M.Sc. from the London School of Economics, and a B.S. from the University of Kansas.<\/p>\n<p align=\"justify\">\n        <strong>About Autolus Therapeutics plc<\/strong><br \/>\n        <br \/>Autolus Therapeutics plc\u00a0(Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL<sup>\u00ae<\/sup>, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rwjuRDZhPHmyMRoATHbuwZJUNIUXD0fZlroreM4kk7CahSeNIBb_0keCmWh-gnYrcqI94V1O7vZMuUFotf8_5ZDRLG9QUYHTleIlQUY_yFYVILitDCbQ-n9G1DZKL1pKFowDeUAtdDH5tobTJZjOvdeBwukdrR3jXm9ZiziBj3bfoMqhEedvDghwbN13CeVb-6hYYkuMq8xiNdMc68BydOHZadH2Ar7v_jzrzOvDdyDUDmGRXG6FN9lsdp0gMfBjbBXnJvXlT2cv2zKc5NBZuA==\" rel=\"nofollow\" target=\"_blank\">www.autolus.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Amanda Cray\u00a0<br \/>+1 617-967-0207\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hzRGfgRLO0yph43H4-qLH4g46iZ-Jt9HG9-B5WKRC3pX36N1wEKXhxnusiCeVn2dL10bPcPGXFCuygQQw1pD3TOKRskNVdP7kKaoSbhULdo=\" rel=\"nofollow\" target=\"_blank\">a.cray@autolus.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjQ3ZDE4NzktNWNhZC00OTgyLWI4ZmMtNWY0OWE2OGM0MmMwLTExMTEyMDEtMjAyNS0xMi0wMS1lbg==\/tiny\/Autolus-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company\u2019s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus\u2019 Board. \u201cAutolus has entered a new phase of growth as a commercial-stage company. Ryan\u2019s deep experience guiding corporate strategy and development will be invaluable to our organization as we continue the momentum of our first commercial launch, and maximize the significant opportunity we have to expand obe-cel\u2019s reach in new indications in a focused &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Autolus Therapeutics Appoints Ryan Richardson to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-914482","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company\u2019s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus\u2019 Board. \u201cAutolus has entered a new phase of growth as a commercial-stage company. Ryan\u2019s deep experience guiding corporate strategy and development will be invaluable to our organization as we continue the momentum of our first commercial launch, and maximize the significant opportunity we have to expand obe-cel\u2019s reach in new indications in a focused &hellip; Continue reading &quot;Autolus Therapeutics Appoints Ryan Richardson to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-01T12:11:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors\",\"datePublished\":\"2025-12-01T12:11:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/\"},\"wordCount\":520,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/\",\"name\":\"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=\",\"datePublished\":\"2025-12-01T12:11:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - Market Newsdesk","og_description":"LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company\u2019s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus\u2019 Board. \u201cAutolus has entered a new phase of growth as a commercial-stage company. Ryan\u2019s deep experience guiding corporate strategy and development will be invaluable to our organization as we continue the momentum of our first commercial launch, and maximize the significant opportunity we have to expand obe-cel\u2019s reach in new indications in a focused &hellip; Continue reading \"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-01T12:11:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors","datePublished":"2025-12-01T12:11:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/"},"wordCount":520,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/","name":"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=","datePublished":"2025-12-01T12:11:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDM1NCM3Mjk4ODI5IzIwOTk2MzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-appoints-ryan-richardson-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=914482"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914482\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=914482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=914482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=914482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}